Saturday 17 October 2026 Export STTK’s income statement to Excel — free account

Shattuck Labs, Inc.

In the quarter to June 2026, revenue fell 10.3%, EPS grew 50.0% and free cash flow grew 1.01%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

5.42 0.11 −1.99%

Follow STTK

Alert me

Market cap: $555.0M
P/E: 0.0×
Fwd P/E: −10.3×
Dividend yield: —
F-score: 4/9
Altman Z: 10.16
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.25

Total sells 0.59

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	—	—	—
Sell	—	—	—	—	—	—	2	2	1	—	—	—

Insider Ownership 33.56%

Capital & Financial Ratios $m

Market Cap 555.01

Revenue 5.61

Net Income (52.57)

Free Cash Flow (41.24)

Net Debt (208.30)

Current Ratio 27.59

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (10.30)

P/S ratio 125.47

P/B ratio 3.33

Past 5Y EPS Growth —

This Y EPS Growth 30.68%

Next Y EPS Growth (6.83%)

Next Y revenue growth (88.89%)

Next 5Y EPS Growth 5.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 67.79%

10-year low 10-year high

P/B against its own 10 years 79.45%

10-year low 10-year high

EV/Sales against its own 10 years 54.47%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	131	73	78	208
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	143	79	82	213

	2023	2024	2025	Q'26
Payables	2	2	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	11	9	7	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	(36.82%)	15.32%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(23.27%)	(22.38%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	1	—	1
’24	1	2	3	0	6
’23	0	0	1	1	2
’22	—	0	0	0	1
’21	2	(4)	2	30	30
’20	3	3	2	1	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(10)	—	—	—
’25	(12)	(10)	(9)	(8)	(40)
’24	(16)	(11)	(16)	(17)	(61)
’23	(26)	(19)	(17)	(19)	(81)
’22	(26)	(16)	(28)	(24)	(94)
’21	(11)	(14)	(13)	(19)	(57)
’20	(10)	2	(11)	(14)	(34)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(10)	—	—	—
’25	(12)	(10)	(9)	(8)	(40)
’24	(16)	(11)	(16)	(17)	(61)
’23	(27)	(19)	(17)	(19)	(82)
’22	(29)	(24)	(29)	(24)	(106)
’21	(14)	(17)	(14)	(21)	(65)
’20	(11)	2	(11)	(14)	(34)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.12)	—	—	—
’25	(0.27)	(0.24)	(0.14)	(0.12)	(0.70)
’24	(0.37)	(0.42)	(0.33)	(0.37)	(1.49)
’23	(0.49)	(0.50)	(0.65)	(0.41)	(2.05)
’22	(0.58)	(0.65)	(0.58)	(0.60)	(2.41)
’21	(0.28)	(0.56)	(0.41)	0.18	(1.07)
’20	(0.86)	(0.81)	(1.54)	(0.31)	(2.36)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	17.51	7.88	1.85	1.33	0.94	0.69	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	60.52	59.57	9.46	7.77	11.76	3.70
People
People	Employees	—	—	—	—	59	85	105	75	44	40
	Revenue/emp, $m	—	—	0.00	0.00	0.17	0.35	0.01	0.02	0.13	0.03
Income, $m
Income, $m	Revenue	—	—	22	10	10	30	1	2	6	1
	Gross margin, %	—	—	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(7)	(24)	(37)	(45)	(102)	(87)	(75)	(49)
	EBT margin, %	—	—	(32.92)	(242.56)	(368.46)	(149.83)	(15,635.74)	(5,268.44)	(1,318.13)	(4,880.90)
	Net income	—	0	(7)	(24)	(37)	(45)	(102)	(87)	(75)	(49)
	Depreciation	—	—	0	0	1	4	4	3	2	3
Per share, $
Per share, $	Revenue	—	—	0.54	1.31	0.64	0.71	0.02	0.04	0.11	0.01
	Earnings	—	—	(0.18)	(3.17)	(2.36)	(1.07)	(2.41)	(2.05)	(1.49)	(0.70)
	Cash flow	—	—	(0.17)	(2.78)	(2.17)	(1.36)	(2.23)	(1.91)	(1.19)	(0.57)
	Capex	—	—	0.00	(0.06)	(0.05)	(0.19)	(0.27)	(0.01)	0.00	0.00
	Free cash flow	—	—	(0.17)	(2.84)	(2.22)	(1.55)	(2.50)	(1.92)	(1.19)	(0.57)
	Book value	—	—	0.91	1.92	19.98	6.47	4.16	3.40	1.57	1.18
	Shares, m	—	—	42	8	16	42	42	43	51	70
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	14.36	14.36	81.81	11.92	3.45	194.36	10.74	45.31
	P/B	—	—	0.00	0.00	2.62	1.32	0.60	2.23	0.77	3.08
	EV/Sales	—	—	1.35	1.35	48.04	2.96	(1.80)	115.53	(2.02)	31.38
	EV/FCF	—	—	(0.51)	(0.51)	(13.88)	(1.37)	0.52	(2.34)	0.19	(4.40)
Cash, $m
Cash, $m	Operating cash flow	—	—	(7)	(21)	(34)	(57)	(94)	(81)	(61)	(40)
	Capex	—	—	(1)	0	(1)	(8)	(12)	0	0	0
	Free cash flow	—	—	(7)	(21)	(34)	(65)	(106)	(82)	(61)	(40)
Balance, $m
Balance, $m	Working capital	—	—	45	22	329	264	160	132	70	75
	Total debt	—	—	—	—	—	—	5	—	—	—
	Net debt	—	—	(60)	(39)	(335)	(269)	(161)	(131)	(73)	(78)
	Shareholders’ equity	—	—	38	15	310	272	176	145	80	82
Returns, %
Returns, %	ROA	—	—	(21.68)	(42.40)	(18.58)	(13.89)	(40.46)	(47.85)	(60.18)	(53.61)
	ROIC	—	—	0.00	0.00	0.00	(948.80)	(434.10)	(408.19)	(758.46)	(744.34)
	ROE	—	—	32.38	105.12	(26.59)	(15.46)	(45.52)	(54.41)	(67.23)	(60.25)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SLN Silence Therapeutics PLC Sponsored ADR	$581.1M	— (loss-making)	— (loss-making)	+197.18% (above 0%: growing)	n/m	+106.95% (above 0%: growing)	97.39%	0.00%	Compare
SGMT Sagimet Biosciences Inc.	$574.7M	— (loss-making)	— (loss-making)	—	n/m	−21.95% (below 0%: shrinking)	100.00%	0.00%	Compare
DBVT DBV Technologies S.A.	$572.6M	— (loss-making)	—	−53.33% (below 0%: shrinking)	n/m	−56.15% (below 0%: shrinking)	100.00%	(7,228.57%)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
DRUG Bright Minds Biosciences Inc.	$534.7M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
FTH Faeth Therapeutics, Inc.	$532.3M	— (loss-making)	—	—	n/m	−174.24% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$552.9M	—	—	−4.77%	—	−56.15%	84.93%	0.00%

All 614 Biotechnology stocks →

Shattuck Labs, Inc. (STTK) key facts

Shattuck Labs, Inc. (STTK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, STTK traded at $5.42, a market capitalization of $555.0 million.
Return on equity was −60.3% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 10.16 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.